Abstracts tagged "Cardiovascular"

Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Tate Johnson¹, Lindsay Helget², Harlan Sayles², Punyasha Roul³, James O'Dell², Ted Mikuls⁴ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…
Abstract Number: 1846 • ACR Convergence 2022
Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
Patrick Webster¹, Yogita Rochlani² and Konstantinos Loupasakis³, ¹Rheumatology Fellow at Montefiore, New York, NY, ²Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ³Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Cardiac sarcoidosis (CS) is potentially life-threatening and it typically causes heart failure, ventricular arrhythmia, AV block or sudden death. CS has been reported to…
Abstract Number: 0257 • ACR Convergence 2022
High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
Qiong Wu, Quanhu Sheng, Danielle Michell, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High density lipoprotein (HDL) is known for its anti-atherogenic cholesterol efflux and antioxidant functions. HDL has additional relevance to rheumatoid arthritis (RA) because of…
Abstract Number: 0660 • ACR Convergence 2022
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Audrey Hagiwara¹, Moumita Bose¹, Aleksandr Stotland¹, Aleksandra Binek¹, Koen Raedschelders¹, Janet Wei¹, C. Noel Bairey Merz¹, Sarah Parker¹, Jennifer Van Eyk¹, Daniel Wallace¹, Mariko Ishimori² and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Health System, Los Angeles, CA
Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
Abstract Number: 0922 • ACR Convergence 2022
Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
Nuria Barbarroja¹, Carlos Pérez-Sánchez¹, Laura Cuesta-Lopez¹, Miriam Ruiz-Ponce¹, Ivan Arias-de la Rosa¹, Antonio Gonzalez², Eva Perez Pampin³, Chamaida Plasencia-Rodriguez⁴, Ana Martinez-Feito⁴, Rafaela Ortega-Castro¹, Jerusalem Calvo-Gutierrez⁵, Alejandro Balsa⁶, Alejandro Escudero-Contreras¹, Eduardo Collantes¹ and Chary López-Pedrera⁷, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ³Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ⁴Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ⁶Hospital La Paz Institute for Health Research, Madrid, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of suffering cardiovascular disease. The analysis of the cardiovascular and cardiometabolic proteome in RA patients…
Abstract Number: 1407 • ACR Convergence 2022
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Reinder Raadsen¹, Laurette van Boheemen¹ and Michael Nurmohamed², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic to…
Abstract Number: 1582 • ACR Convergence 2022
Allopurinol Use and Risk of Acute Coronary Syndrome in Patients with Incident Gout: A Population-based Study in Sweden
Panagiota Drivelegka¹, Lennart Jacobsson², Karin Bengtsson³ and Mats Dehlin⁴, ¹Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ³Department of Rheumatology and Inflammation research, University of Gothenburg, Salhgrenska Academy, Gothenburg, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Gout is associated with an increased risk of cardiovascular disease, with accumulated evidence that gout is an independent risk factor. Whether allopurinol use alters…
Abstract Number: 1856 • ACR Convergence 2022
Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram
Tsz Ho Luk¹, Weng Nga Lao¹, Steve Pang¹, Ho So², Tak Lung Wong³ and Yan Ki Tang⁴, ¹Kwong Wah Hospital, Hong Kong, Hong Kong, ²Chinese University of Hong Kong, Hong Kong, Hong Kong, ³KWH, Kowloon, Hong Kong, ⁴Kwong Wah Hospital, Hong Kong, China
Background/Purpose: Idiopathic inflammatory myopathy (IIM) poses elevated risk of cardiovascular event and mortality, similar to other autoimmune rheumatic diseases. With the use of computer tomography…
Abstract Number: 0284 • ACR Convergence 2022
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
Daniela Chicre¹, Alisson Pugliesi¹, Manoel Barros Bértolo¹, Vani de Abreu Souza Filho¹ and Luiz Sérgio F Carvalho², ¹Universidade Estadual de Campinas, Campinas, São Paulo, Brazil, ²Clarity: Inteligência em Saúde, Brasília, Brazil
Background/Purpose: The ORAL-Surveillance trial showed important data on the comparative safety between Tofacitinib and TNF inhibitors (TNFi) in the treatment of RA, leading to safety…
Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Gustavo Balbi¹, Flavio Victor Signorelli², Ana Paula Gandara³, Indira Azam³, Dilson Marreiros³, Luciano Drager³ and Danieli Castro Oliveira de Andrade⁴, ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ³University of São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
Abstract Number: 0981 • ACR Convergence 2022
QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study
Tanmayee Bichile¹, Susan Manzi² and Tarun Sharma³, ¹Allegheny Health Network, Gibsonia, PA, ²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ³Allegheny Health Network, Pittsburgh, PA
Background/Purpose: The effect of hydroxychloroquine (HCQ) on QTc interval in patients with rheumatic diseases is under scrutiny since the COVID-19 pandemic, however studies have shown…
Abstract Number: 1408 • ACR Convergence 2022
In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
Reinder Raadsen¹, Rabia Agca², Maarten Boers³, Vokko van Halm², Mike Peters⁴, Yvo Smulders², Joline Beulens², Marieke Blom², Coen Stehouwer⁵, Alexandre Voskuyl², Willem Lems⁶ and Michael Nurmohamed⁷, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁴Amsterdam UMC; UMC Utrecht, Amsterdam, Netherlands, ⁵MUmc, Amsterdam, Netherlands, ⁶Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁷Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: We have documented that patients with rheumatoid arthritis (RA) are at increased risk to develop cardiovascular disease (CVD) compared to the general population, even…
Abstract Number: 1605 • ACR Convergence 2022
Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study
Bas Dijkshoorn¹, Daisy Vedder¹, Anna Rudin², Dan Nordstrom³, Bjorn Gudbjornsson⁴, Kristina Lend⁵, Till Uhlig⁶, Espen Haavardsholm⁶, Gerdur Maria Grondal⁷, Merete L Hetland⁸, Marte Heiberg⁶, Mikkel Østergaard⁹, Kim Horslev-Petersen¹⁰, Jon Lampa¹¹, Ronald van Vollenhoven¹², Aleksandra antovic¹³ and Michael Nurmohamed¹⁴, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ³Helsinki University Hospital, Helsinki, Finland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵The Karolinska Institute, Stockholm, Sweden, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Landspitali University Hospital, Centre for Rheumatology Research, Reykjavik, Iceland, ⁸Rigshospitalet, Glostrup, Denmark, ⁹Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ¹⁰Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ¹¹Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Karolinska Institute, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹⁴Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of venous thromboembolism. Thus far, there have not been any comparative studies investigating the…
Abstract Number: 1951 • ACR Convergence 2022
Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
Claudia De Luis zarate¹, Cristina Almeida Santiago², Maria Vanesa Hernández Hernández³, antonia De Vera González⁴, Alejandra González Delgado⁴, Juan Carlos Quevedo Abeledo⁵ and Ivan Ferraz Amaro⁶, ¹Hospital Universitario de Canarias, Puerto de la Cruz, Spain, ²Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³HUC, San Cristóbal de la, Spain, ⁴HOSPITAL UNIVERSITARIO DE CANARIAS, Santa Cruz de Tenerife, Spain, ⁵Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, ⁶Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain
Background/Purpose: Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis…
Abstract Number: 0317 • ACR Convergence 2022
Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression
Ivan Ferraz Amaro¹, maría García-González², carmen Ferrer-Moure², Fuensanta Gómez-Bernal², Antonia De Vera-González², Alejandra González Delgado², Agustín Francisco González-Rivero², Yolanda Fernández-Cladera², Juan Carlos Quevedo Abeledo³ and Federico Díaz-González⁴, ¹Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife
Background/Purpose: Activation of the classical complement (C) pathway by immune complexes is a characteristic of patients with systemic lupus erythematosus (SLE). Accelerated consumption outstrips synthesis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].